ZOETIS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 171.9 USD | -0.28% |
|
+0.34% | -12.91% |
ETFs positioned on Zoetis Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.05% | 6 M€ | +3.89% | ||
| 0.05% | 105 M€ | +3.74% | - | |
| 0.04% | 32 M€ | +0.75% | - | |
| 0.03% | 8 M€ | +0.71% | - | |
| 0.03% | 756 M€ | +0.68% | - | |
| 0.03% | 2 M€ | +3.16% | - | |
| 0.02% | 54 M€ | +0.86% | - | |
| 0.02% | 6 M€ | -4.26% | - | |
| 0.02% | 112 M€ | +4.04% | - | |
| 0.01% | 169 M€ | -0.70% | - | |
| 0.01% | 3 M€ | +6.01% | - | |
| 0.02% | 34 M€ | +3.46% | - | |
| 6.85% | 129 M€ | +7.90% | - |
Zoetis Inc. specializes in developing, manufacturing and marketing of animal health products. Net sales break down by activity as follows:
- pets (64.4%): cats and dogs (94.9% of net sales) and horses (5.1%);
- livestock (34.5%): cattle (51.6% of sales), swine (20.2%), poultry (17.1%), fish (7.6%) and other (3.5%);
- other (1.1%).
Net sales break down by family of products into parasiticides (23%), vaccines (21.3%), dermatological products (16.4%), anti-infectives (13.4%), medical food additives (4.5%), diagnostic products (4.4%) and other (17%).
At the end of 2022, the group has 29 production sites worldwide.
The United States accounts for 53.4% of net sales.
Sector
Pharmaceuticals
Calendar
2024-07-31
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
171.9
USD
Average target price
211.2
USD
Spread / Average Target
+22.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.91% | 78.65B | |
| +22.15% | 8.77B | |
| +25.50% | 3.68B | |
| -2.50% | 3.21B | |
| +12.67% | 1.77B | |
| -25.16% | 1.24B | |
| -27.23% | 1.2B | |
| -18.50% | 1.05B | |
| -7.57% | 951M | |
| -2.72% | 901M |
- Stock Market
- Equities
- ZTS Stock
- Funds and ETFs Zoetis Inc.
